Form 4: Cognition Therapeutics Director Aaron Fletcher Reports RSU Grant and Extensive Indirect Holdings

A recent SEC Form 4 filing reveals that Cognition Therapeutics Inc. Director Aaron G.L. Fletcher was granted 34,000 restricted stock units (RSUs) and details his significant indirect beneficial ownership through various Bios Equity Partners entities.

Summary

• Aaron G.L. Fletcher, a Director and 10% Owner of Cognition Therapeutics Inc. (CGTX), reported the acquisition of 34,000 shares of Common Stock, represented by Restricted Stock Units (RSUs), on June 18, 2025.
• These RSUs were acquired at a price of $0 and represent a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• The RSUs are set to vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, contingent on Dr. Fletcher's continuous service as a director.
• Dr. Fletcher holds these equity-based awards as a nominee for BP Directors, LP, indicating that BP Directors, LP may be deemed the direct or indirect beneficial owner.
• The filing details a complex web of indirect beneficial ownership, with Dr. Fletcher, Leslie W. Kreis, Jr., and various Bios and Cavu entities (including Bios Capital Management, Bios Advisors GP, LLC, Cavu Management, and Cavu Advisors LLC) sharing voting and investment control over a substantial number of shares held by multiple Bios funds.
• Total indirect beneficial ownership reported across various Bios funds includes: Bios Clinical Opportunity Fund, LP (500,095 shares), Bios Fund III NT, LP (326,733 shares), Bios Fund III QP, LP (2,021,906 shares), Bios Fund III, LP (309,748 shares), Bios Memory SPV I, LP (1,424,014 shares), Bios Fund I, LP (418,926 shares), Bios Fund I QP, LP (245,029 shares), Bios Fund II, LP (78,298 shares), Bios Fund II QP, LP (255,765 shares), Bios Fund II NT, LP (34,238 shares), and Bios Memory SPV II, LP (385,248 shares).
• This Form 4 is one of two filings related to the same event, split due to the SEC's EDGAR system limit of 10 reporting persons per Form 4.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It primarily reports a routine insider transaction (RSU grant) and details a complex but established beneficial ownership structure. The RSU grant aligns director incentives with shareholder value, which is a positive, but there are no significant financial or operational updates to drive a strong sentiment.

Positives

• The grant of 34,000 RSUs to Director Aaron G.L. Fletcher aligns his interests with long-term shareholder value through equity-based compensation.
• The vesting schedule for the RSUs incentivizes Dr. Fletcher's continued service as a director, providing stability to the board.

Negatives

• The complex structure of indirect beneficial ownership through numerous entities may require careful scrutiny for transparency and potential conflicts of interest, though this is common for institutional investors.

Risks

• The vesting of RSUs is contingent on Dr. Fletcher's continuous service as a director; any cessation of service before the vesting date would result in forfeiture of the unvested units.
• The beneficial ownership disclaimers by reporting persons, except to the extent of their pecuniary interest, indicate that the reported shares may not be fully controlled by each listed entity or individual for all purposes.

Future Outlook

The 34,000 RSUs granted to Director Aaron G.L. Fletcher are expected to vest in full by June 18, 2026, or earlier upon the Issuer's next annual meeting of stockholders, provided his continuous service as a director.

Industry Context

This Form 4 filing is a standard disclosure of insider transactions, reflecting a director's equity compensation and the beneficial ownership structure of a significant institutional investor (Bios Equity Partners) in a publicly traded biotechnology company. Such grants are common practice to align management and director incentives with shareholder interests.

Management Changes

Corporate Governance

Related Party Transactions

• Aaron G.L. Fletcher holds certain equity-based awards as a nominee for BP Directors, LP, which may be deemed the direct or indirect beneficial owner of these securities.
• The filing details extensive indirect beneficial ownership relationships among Aaron G.L. Fletcher, Leslie W. Kreis, Jr., Bios Capital Management, Cavu Management, Bios Advisors GP, LLC, Cavu Advisors LLC, and numerous Bios investment funds (e.g., Bios Fund I, II, III, Bios Memory SPV I, II, Bios Clinical Opportunity Fund), all sharing voting and investment control over the reported shares.

Stakeholder Impact

• Shareholders: The RSU grant aligns a director's interests with shareholder value. The detailed beneficial ownership structure provides transparency regarding significant institutional holdings.
• Management: The RSU vesting schedule incentivizes the director's continued service and commitment to the company.

Next Steps

• The 34,000 RSUs granted to Aaron G.L. Fletcher are expected to vest on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Another Form 4 filing related to the same event, filed by Mr. Kreis, is expected to provide additional details on beneficial ownership for other reporting persons.

Key Dates

Keywords

SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSU Grant, Cognition Therapeutics Inc., CGTX, Aaron G.L. Fletcher, Bios Equity Partners, Director Compensation, Equity Compensation, Investment Funds